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SObjective: Atrial fibrillation is common after esophagectomy. The objective of this study was to determine the
efficacy and safety of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomy.
Methods: Eighty patients undergoing transthoracic esophagectomy were randomly, prospectively assigned to re-
ceive amiodarone (n ¼ 40) or no prophylaxis (control group, n ¼ 40). Amiodarone-treated patients received the
drug by continuous infusion, initiated at the time of induction of anesthesia, at a rate of 0.73 mg/min (43.75 mg/h),
and continued for 96 hours (total dose 4200 mg). The primary end point was atrial fibrillation requiring treatment.
Secondary end points included any atrial fibrillation lasting longer than 30 seconds and postoperative hospital and
intensive care unit stays.
Results: There were no significant differences between the amiodarone and control groups in demographic char-
acteristics, comorbid conditions, or preoperative or postoperative use of b-blockers or calcium-channel blockers.
The incidence of atrial fibrillation requiring treatment was lower in the amiodarone group than in the control group
(15% vs 40%, P ¼ .02, relative risk reduction 62.5%). There were no significant differences between the amio-
darone and control groups in median hospital stay (11 days vs 12 days, P¼ .31) or median intensive care unit stay
(68 hours vs 77 hours, p ¼ .097). There were no significant difference between the groups in the incidences of
adverse effects.
Conclusions:Amiodarone prophylaxis significantly reduced the incidence of atrial fibrillation after transthoracic
esophagectomy. (J Thorac Cardiovasc Surg 2010;140:45-51)Earn CME credits at
http://cme.ctsnetjournals.org
Atrial fibrillation (AF) is a common complication after trans-
thoracic esophagectomy, with reported incidences ranging
from 13% to 46%.1-5 AF after esophagectomy may result
in a variety of adverse symptoms2 and hemodynamic
instability.2,3,5 Postesophagectomy AF has been reported to
prolong stay in an intensive care unit (ICU) or intermediate
care unit5 and to prolong the median total hospital stay by
5 days.2 Strategies for prevention of AF after esophagectomy
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The Journal of Thoracic and CAmiodarone is an antiarrhythmic agent that has been shown
to be effective for the management of AF unrelated to
surgery.6 In addition, numerous prospective trials have
reported that amiodarone is effective for preventionofAFafter
cardiac surgery,7-10 and evidence also supports the efficacy of
amiodarone for prophylaxis against AF after anatomic
pulmonary resection.11,12 Amiodarone has been
recommended for prevention of AF after coronary artery
bypass grafting by the American Heart Association,
American College of Cardiology, and European Society of
Cardiology (class IIa, level of evidenceA).13Despite the docu-
mented efficacy of amiodarone for prophylaxis against AF af-
ter coronary artery bypass grafting and pulmonary resection
procedures, no prospective randomized data exist regarding
its efficacy in prevention of AF after esophagectomy. The
purpose of this study was to test the hypotheses that amiodar-
one is effective and safe in the prevention of AF after esopha-
gectomy and that reduction in the incidence of AF would
reduce the durations of postoperative hospital and ICU stays.MATERIALS AND METHODS
Patients
This study was conducted at Indiana University Hospital of Clarian
Health Partners, a 270-bed tertiary care hospital located in Indianapolis,
Ind. All patients older than 40 years undergoing transthoracic esophagec-
tomy through an open or minimally invasive approach were evaluated for
potential enrollment. Exclusion criteria were as follows: history of AF or
atrial flutter, AF or atrial flutter requiring treatment occurring during theardiovascular Surgery c Volume 140, Number 1 45
Abbreviations and Acronyms
AF ¼ atrial fibrillation
ICU ¼ intensive care unit
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Ssurgical procedure, previous severe adverse reaction or contraindication to
amiodarone (pulmonary fibrosis, thyroid dysfunction, hepatotoxicity), re-
ceipt of a Vaughan Williams class I or III antiarrhythmic drug or other
QT interval–prolonging drug within 5 half-lives of the administration of
amiodarone, pretreatment Bazett’s-corrected QT (QTc) interval longer
than 450 ms, and serum alanine transaminase or aspartate transaminase con-
centration greater than 3 times the upper limit of normal. This study was ap-
proved by the institutional review board at Indiana University-Purdue
University-Indianapolis. All patients provided written, informed consent
before participation.
Study Protocol
This was a prospective, randomized, parallel-groups study. A description
of patients screened, consenting, randomly assigned, and enrolled in the
study is shown in Figure 1. Patients were randomly assigned to receive
amiodarone (amiodarone group) or no amiodarone (control group). The spe-
cific randomization sequence was computer generated. Patients randomly
allocated to the amiodarone group received a continuous intravenous infu-
sion of 1050 mg amiodarone in 1000 mL 5% dextrose, which was initiated
at anesthesia induction, administered at a rate of 0.73 mg/min (43.75 mg/h),
and continued for 96 hours (total dose 4200 mg). Patients randomly
allocated to the control group did not receive amiodarone prophylaxis. Post-
operative care was according to standard protocol, which included analgesia
with intravenous and epidural narcotics. Continuous telemetric electrocar-
diographic monitoring was initiated intraoperatively. After esophagectomy,
patients were admitted either to an ICU or to a non-ICU step-down unit, at
the decision of the surgeon according to a standard care plan. Decisions re-
garding transfer of patients from the ICU to a non-ICU step-down unit and
decisions regarding discharge from the hospital were made according to
standard hospital criteria. Throughout the hospital course, all study patients
underwent continuous monitoring with a telemetric electrocardiograph
equipped with a triggered alarm and recording systems for abnormal
rhythms. Any patient in whom AF developed, regardless of assignment to
the amiodarone or control group, was managed by critical care attending
physicians, cardiology consultants, surgical residents, or surgical attending
physicians during the course of routine postoperative care with rate control
or rhythm conversion strategies as deemed appropriate. All patients rou-
tinely underwent contrast esophagraphy to evaluate upper gastrointestinal
integrity before resumption of oral nutrition on the 7th postoperative day
or thereafter as early as the patient’s condition would permit.
Blood for determination of serum amiodarone and desethylamiodarone
(DEA) concentrations was collected in 10-mL nonheparinized evacuated
tubes (Vacutainer; Becton, Dickinson and Company, Franklin Lakes, NJ)
at 9:00 AM on postoperative day 2. The blood samples were placed on ice,
allowed to clot, and then centrifuged at 2500 rpm for 25 minutes. Serum
was harvested and stored at70C until analysis. Serum amiodarone and
DEA concentrations were determined with high-performance liquid chro-
matography (ARUP Laboratories, Salt Lake City, Utah).14 The lower and
upper limits of detection of this assay for amiodarone and DEA were
0.3 mg/mL and 6.0 mg/mL, respectively.
Study End Points
The primary end point was AF requiring treatment because of a rapid
ventricular rate, symptoms such as shortness of breath and fatigue, or hemo-
dynamic compromise.8 Prespecified secondary end points were as follows:
(1) total postoperative hospital stay, (2) ICU stay, (3) incidence of adverse46 The Journal of Thoracic and Cardiovascular Surgeeffects, and (4) cost of hospitalization from the time of surgery until dis-
charge from the hospital. An additional end point was evaluated post hoc:
the incidence of AF (treated or untreated) lasting longer than 30 seconds.13,15
Adverse effects were defined as follows: hypotension was a systolic blood
pressure less than 90 mm Hg; bradycardia was a heart rate less than
50 beats/min; and respiratory complications were adult respiratory distress
syndrome, pneumonia, pulmonary fibrosis, or atelectesis necessitating
bronchoscopy or reintubation. Hospital charges were obtained from the
Indiana University Hospital Claims Management Database. Hospital-
derived cost:charge ratios were applied to convert hospital charges to costs.
Sample Size Determination and Data Analysis
The a priori sample size calculation was based on an expected incidence
of AF of 40% in the control group.1,5 The sample size of 40 patients per
group allowed detection of an absolute difference in incidence of AF of
22.5% (corresponding to a relative risk reduction of 56%) at a power of
.80 with an a of .05. Statistical analyses were performed with the
statistical software SPSS 16 (SPSS Inc, Chicago, Ill). Normality of
continuous data was determined with the Kolmogorov–Smirnov test.
Continuous data that were normally distributed were analyzed with the
Student unpaired t test. Continuous data that were not normally
distributed were analyzed with the nonparametric Wilcoxon rank sum
test. Noncontinuous data were analyzed with the c2 test or Fisher’s Exact
test as appropriate. Kaplan–Meier time-to-event curves were constructed,
and differences between the groups were assessed with log-rank analysis.
The funding source had no role in data analysis or interpretation.
RESULTS
Study Population
Between September 2004 and November 2008, a total of
80 patients were enrolled in the study, with 40 patients ran-
domly allocated to each arm (Figure 1). There were no sig-
nificant differences between experimental and control
groups with respect to demographic characteristics, comor-
bid conditions, and preoperative or postoperative medica-
tions, including b-blockers and calcium-channel blockers
(Table 1). The indication for surgery was esophageal cancer
in 35 of 40 patients (87.5%) in the amiodarone group and 37
of 40 patients (92.5%) in the control group (P ¼ .71). The
remaining patients underwent surgery for perforation and
achalasia (amiodarone group 5/40 [12.5%], control group
3/40 [7.5%], P ¼ .71).
Most patients (73/80, 91.3%) underwent esophagectomy
through an open transthoracic approach; the remainder
(7/80, 8.7%) were operated on through a closed transthoracic
approach (Table 1). Patients who underwent esophagectomy
for malignancy also underwent en bloc periesophageal and
celiac lymph node dissections. The stomach was the conduit
of choice for reconstruction and was used in 77 patients in
this study. Small bowel (n ¼ 1, amiodarone group) and large
bowel (n ¼ 2, both control group) reconstructions were per-
formed when the stomach was not usable.
Incidence of AF
Overall, 22 patients (27.5%) needed treatment for deve-
lopment of AF. The incidence of postoperative AF was sig-
nificantly lower in the amiodarone group (6/40, 15.0%) than
in the control group (16/40, 40.0%, relative risk 0.38 [95%ry c July 2010
FIGURE 1. Summary of patients screened, consenting, randomized, and included in study. Pre-op, Preoperative; OR, operating room.
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corresponded to a 62.5% reduction in relative risk. With
a 25% reduction in the absolute incidence of AF, the number
of patients needing prophylactic treatment with amiodarone
to prevent 1 episode of AF would be 4.0 (95% confidence
interval 2.3–16.1). The mean maximum recorded heart rates
in the patients in whom AF developed were 157  11 and
164  14 beats/min in the amiodarone and control groups,
respectively (P ¼ .01). The mean time from surgery to the
onset of electrocardiographically documented AF was lon-
ger in the amiodarone group than in the control group
(67.5  31.3 vs 46.2  19.0 hours), but this difference did
not reach statistical significance (P ¼ .06). Of the 6 patientsThe Journal of Thoracic and Cin the amiodarone group in whom AF developed, 2 (33.3%)
were discharged from the hospital in AF, compared with 3 of
16 patients (18.8%) in the control group (P ¼ .58).
Using the AF definition of treated or untreated lasting lon-
ger than 30 seconds, the results were identical to those ob-
tained with the definition as AF requiring treatment. The
incidence of postoperative AF lasting longer 30 seconds
was significantly lower in the amiodarone group (6/40,
15.0%) than in the control group (16/40, 40.0%, relative
risk 0.38 [95% confidence interval 0.16–0.86], P ¼ .02],
which corresponded to a 62.5% reduction in relative risk.
There were no instances of AF lasting longer than 30 sec-
onds that did not require treatment.ardiovascular Surgery c Volume 140, Number 1 47
TABLE 1. Characteristics of patients enrolled
Characteristic
Amiodarone
(n ¼ 40)
Control
(n ¼ 40)
P
value
Age (y, mean  SD) 61  10 63  9 .48
Male 85.0% 82.5% >.99
White 97.5% 100% >.99
Preoperative weight
(kg, mean  SD)
86.6  13.5 82.8  21.1 .70
Comorbid conditions
Hypertension 52.5% 50.0% >.99
Heart disease* 5.0% 10.0% .68
Diabetes mellitus 15.0% 10.0% .74
Chronic obstructive
pulmonary disease
5.0% 7.6% >.99
Preoperative chemotherapy or
radiation
60.0% 52.5% .65
Preoperative medications
b-blockers 25.0% 25.0% >.99
Calcium channel blockersy 2.5% 5.0% >.99
Statins 22.5% 17.5% .78
Nonsteroidal anti-
inflammatory drugs
2.5% 10.0% .36
Angiotensin-converting
enzyme inhibitors
32.5% 25.0% .62
Postoperative medications
b-blockers 27.5% 20.0% .60
Discontinuation of
preoperative b blocker
12.5% 20.0% .55
Calcium channel blockersy 2.5% 5.0% >.99
Statins 15.0% 15.0% >.99
Nonsteroidal anti-
inflammatory drugs
2.5% 5.0% >.99
Angiotensin converting-
enzyme inhibitors or
angiotensin receptor
blockers
25.0% 15.0% .40
Type of surgery
Ivor Lewis 42.5% 50.0%
Three port 57.5% 50.0% .65
Video-assisted
thoracoscopic surgery
10.0% 7.5% .71
Intraoperative data
Estimated blood loss (mL,
mean  SD)
337  143 357  274 .71
Patients receiving
transfusions
20.0% 32.5% .31
Units of blood transfused
(mean  SD)
2.6  1.0 2.5  1.8 .88
Duration of surgery
(min, mean  SD)z
448  106 447  85 .86
*Heart disease includes history of myocardial infarction, coronary artery disease, and/
or heart failure. yDiltiazem or verapamil. zFrom anesthetic induction to skin closure.
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Hospitalization
The mean postoperative hospital and ICU stays in the
overall study population were 15.2  11.2 days (median
12 days) and 152  259 hours (median 70 hours), respec-48 The Journal of Thoracic and Cardiovascular Surgetively. Considering all enrolled patients, there was a trend to-
ward a longer median total hospital stay among patients in
whom AF developed than among those who did not have
AF develop (15.0 vs 11.5 days, P¼ .06). There was a signif-
icant difference in median ICU stay between patients in
whom AF developed and those in whom it did not (144 vs
67 hours, P¼ .006). Median total postsurgical hospital stays
in the amiodarone and control groups were similar (11 vs 12
days, respectively, P¼ .31). In addition, there was no signif-
icant difference in median ICU stay between amiodarone-
treated and control patients (68 vs 77 hours, P ¼ .097).
The total median cost of hospitalization in the amiodarone
group was $24,153, which was not significantly different
from that in the control group ($24,977, P ¼ .93).
Postoperative Adverse Events, Morbidity, and
Mortality
Adverse events in both groups are presented in Table 2.
There were no significant differences between amiodarone
and control groups with respect to the incidences of hypoten-
sion, bradycardia, respiratory complications, or other ad-
verse effects. Amiodarone therapy was discontinued in 2
(5.0%) patients as a result of hypotension requiring
extended vasopressor therapy.
There were a total of 2 operative deaths, both in the con-
trol group. One patient died as a result of myocardial infarc-
tion on the 11th postoperative day. The other patient died of
toxic megacolon on the 13th postoperative day.
Serum Amiodarone and DEA Concentrations
Mean serum amiodarone and DEA concentrations in the
treatment group on postoperative day 2 were 1.15  0.23
mg/mL and 0.032  0.095 mg/mL, respectively. There was
no significant difference in mean serum amiodarone concen-
tration between patients in whom postoperative AF did not
develop and those in whom it did (1.23  0.37 vs 1.07 
0.22 mg/mL, P ¼ .31). There was no significant difference
in mean serum DEA concentration between patients in
whom postoperative AF did not develop and those who
did have postoperative AF (0.047  0.062 mg/mL vs
0.022  0.012 mg/mL, P ¼ .34).
DISCUSSION
AF is a common complication after transthoracic esopha-
gectomy. Mechanisms of AF development after esophagec-
tomy are currently unknown. AF occurring after coronary
artery bypass grafting may be a result of enhanced activity
of the sympathetic nervous system,16 stimulation of the re-
nin–angiotensin–aldosterone system,17 or postoperative in-
flammation.18 Mechanisms of AF after pulmonary
resection are unclear, although some evidence suggests
that elevated right heart pressure may play a significant
role.19 In addition, stress-mediated enhancement of auto-
nomic nervous system activity may contribute to AF afterry c July 2010
FIGURE 2. Kaplan–Meier cumulative incidence of atrial fibrillation (log-rank P ¼ .009).
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Spulmonary resection.20 There are conflicting data regarding
the potential role of inflammation in the etiology of AF after
pulmonary resection. Although mechanisms of AF after
esophagectomy have not been determined, risk factors for
this complication have been investigated and include age
older than 65 years, male sex, history of heart disease,
chronic obstructive pulmonary disease, and postoperative
thoracogastric dilatation.21
Amiodarone is an antiarrhythmic agent that has been
shown to be effective for the management of AF not related
to surgery.6 Amiodarone inhibits sodium, potassium, and
calcium conductance and possesses noncompetitive a- and
b-blocking activity.6 The drug’s antiarrhythmic effects
have been primarily attributed to inhibition of sodium and
potassium channels, prolonging atrial repolarization and ac-
tion potential duration. Amiodarone has been widely studied
for the prevention of AF after cardiac surgery7-10 and has
also been shown to be effective in reducing the incidenceTABLE 2. Postoperative adverse events and morbidity
Amiodarone (n ¼
Cardiovascular complications
Hypotension* 21 (52.5%)
Bradycardiay 2 (5.0%)
QTc interval>500 ms 1 (2.5%)
Ventricular tachycardia 0 (0%)
Respiratory complicationsz 9 (22.5%)
Adult respiratory distress syndrome 0 (0%)
Pneumonia 6 (15.0%)
Atelectasis 3 (7.5%)
Other
Pericardial effusion 1 (2.5%)
Anastomotic leak 1 (2.5%)
All data represent numbers of patients. *Systolic pressure less than 90 mm Hg. yHeart rate
syndrome, pneumonia, pulmonary fibrosis, and atelectesis necessitating bronchoscopy or r
The Journal of Thoracic and Cof AF after pulmonary resection.11,12 The efficacy of
amiodarone in prevention of AF after esophagectomy has
not been previously studied, however; in fact, there have
been no previously published studies evaluating the
efficacy of any drug in the prevention of AF in
a noncardiac thoracic surgical population consisting solely
of patients undergoing esophagectomy. Bayliff and
colleagues22 did conduct a randomized, placebo-controlled
evaluation of oral propranolol for prevention of arrhythmias
in 99 patients undergoing noncardiac thoracic surgery, 31 of
whom underwent esophagectomy. Overall, the incidence of
postoperative tachyarrhythmias (including AF, atrial flutter,
sinus tachycardia, supraventricular tachycardia, and ventric-
ular tachycardia) requiring treatment was 6% in the propran-
olol group, compared with 20% in the placebo group
(p ¼ .071). The incidence of hypotension and bradycardia,
however, was significantly higher in the propranolol-
treated group. Among the patients who underwent40) Control(n ¼40) P value
19 (45.0%) .66
1 (2.5%) >.99
0 (0%) >.99
2 (5.0%) .49
9 (22.5%) >.99
0 (0%) >.99
5 (12.5%) >.99
4 (10.0%) >.99
1 (2.5%) >.99
2 (5.0%) >.99
less than 50 beats/min. zRespiratory complications include adult respiratory distress
eintubation.
ardiovascular Surgery c Volume 140, Number 1 49
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Sesophagectomy, the incidence of AF was low (7.1% in the
placebo group vs 0% in the propranolol group).
In our prospective, randomized study, intravenous admi-
nistration of amiodarone was associated with a 62.5% re-
duction in the relative risk of AF after esophagectomy. In
addition, amiodarone prophylaxis was associated with a rel-
atively low incidence of adverse effects. There were no sig-
nificant differences between the amiodarone and control
groups in the incidences of hypotension, bradycardia, respi-
ratory adverse effects, and QTc-interval prolongation or
in-hospital mortality. The reduction in the incidence of AF
related to amiodarone prophylaxis was not, however, associ-
ated with significant reductions in median ICU stay, total
hospital stay, or cost of hospitalization. In our study, the me-
dian ICU stay was significantly longer among patients in
whom AF developed than among those in whom AF did
not develop, independent of group assignment, and there
was a nonsignificant trend toward a longer total hospital
stay among patients in whom AF developed. It is possible
that a reduction in the incidence of AF associated with pro-
phylactic amiodarone might result in significant decreases in
hospital stay and corresponding costs with a larger sample
size or with postoperative care strategies of ‘‘fast tracking’’
for early hospital discharge.
The definition of AF used in this study was AF requiring
treatment because of a rapid ventricular rate, symptoms such
as shortness of breath and fatigue, or hemodynamic compro-
mise.8 We chose this definition to reflect clinically important
AF; we did not want to consider brief runs of AF that were
asymptomatic and did not require treatment. In view of the
unblinded nature of the study, however, we also performed
a post hoc analysis defining AF as any AF that lasted longer
than 30 seconds.13,15 When applying this more stringent
definition of AF, the results of the study were identical,
because no patients with AF of at least 30 seconds in
duration were untreated. Therefore, regardless of which
AF definition was used, amiodarone significantly reduced
the incidence of AF among patients undergoing
esophagectomy in this study.
In this investigation, amiodarone was administered by
continuous intravenous infusion for a period of 96 hours.
In previous studies of postoperative AF prophylaxis, amio-
darone was administered orally or by nasogastric tube,7,9
or by a combination of intravenous administration
followed by oral routes.12 Oral or nasogastric administration
of amiodarone after esophagectomy is unfeasible for a num-
ber of reasons. After esophagectomy, some patients undergo
nasogastric tube placement, with oral intake withheld for
a period of approximately 7 days, whereas other patients un-
dergo jejunostomy tube placement for immediate feeding.
Previous data have indicated that serum amiodarone concen-
trations are substantially reduced when the drug is adminis-
tered by nasogastric tube after esophagectomy.23 This may
be because of poor bioavailability of amiodarone when50 The Journal of Thoracic and Cardiovascular Surgeadministered into the stomach conduit or as a result of amio-
darone’s adherence to or adsorption by the nasogastric
tube.24 Because amiodarone is absorbed in the duodenum,
there are no published data regarding bioavailability of
amiodarone administered through a jejunostomy tube. For
these reasons, it seems prudent to avoid enteral administra-
tion of amiodarone to patients during the immediate postop-
erative period after esophagectomy.
Patients were excluded from our study after provision of
informed consent if AF developed intraoperatively, which
was an a priori exclusion criterion. These patients were ex-
cluded because the purpose of the study was to test the hy-
pothesis that amiodarone is effective and safe in
prevention of AF after esophagectomy, rather than during
the surgical procedure itself. It is uncertain whether the
mechanisms and clinical outcomes associated with intrao-
perative AF are similar to those that have been clearly docu-
mented in association with postesophagectomy AF.25 In our
study, 7 of 87 patients (8.0%) who provided informed con-
sent and were not excluded for other reasons had AF develop
intraoperatively. Previous data have found the incidence of
intraoperative AF to be as high as 17.1%. The clinical sig-
nificance of intraoperative AF and the potential benefits as-
sociated with its prevention require further study.
The incidence of AF in the control group in our study was
40%. This incidence of postesophagectomy AF is similar to
incidences reported in some previous studies (37%–
46%)1,5 but substantially higher than those (13%–22%)
reported in other studies.2-4 Most patients in this study
underwent surgery for esophageal cancer, and it has been
our standard surgical approach to perform a wide en bloc
mediastinal dissection from the pericardium anteriorly to
the aorta posteriorly in these cases. The high incidence of
AF in our control population could at least in part be
a result of pericardial irritation related to this surgical
approach. In addition, a substantial proportion of our
patients also received preoperative chemotherapy and
radiation, the latter of which might further predispose
patients toward postoperative pericardial inflammation,
potentially contributing to a relatively high incidence of AF.
Blood for determination of serum amiodarone and DEA
concentrations was obtained on postoperative day 2, which
is the median time at which postoperative AF has been re-
ported to occur.4 There was no significant difference in
mean serum amiodarone or DEA concentration between
those patients in whom AF developed and those in whom
it did not. Further study is required to determine whether
a ‘‘threshold’’ serum amiodarone concentration exists for
optimal prevention of AF after esophagectomy.
Limitations of this investigation include the lack of a dou-
ble-blind, placebo-controlled design. Although treatment of
AF was left to the discretion of the treating physician, the
thresholds for assessment of hemodynamic instability and
patient symptoms were similar among the treatingry c July 2010
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Sphysicians and between the study groups. Additionally, al-
though our study was adequately powered to detect signifi-
cant differences in the incidence of AF between the
amiodarone-treated and control groups, larger studies are
necessary for accurate determination of differences in post-
operative hospital stay and cost of hospitalization. Larger
studies might also help to detect infrequently occurring ad-
verse effects associated with amiodarone therapy. The find-
ings of this study provide support for a large, multicenter,
double-blind, placebo-controlled trial.
Prophylactic administration of intravenous amiodarone
reduced the incidence of AF after transthoracic esophagec-
tomy. Amiodarone prophylaxis against AF should be con-
sidered for this population.
We acknowledge Katy Trinkley and Neena Phadke for their
assistance with data collection and Lang Li, PhD, for his review
of the statistical analysis.
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